Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2024
17/7 12:25
Company Announcement Net sales of DARZALEX ® in the second quarter of 2024 totaled USD 2,878 million Genmab receives royalties on worldwide net sales from Janssen Biotech, Inc. (Janssen) COPENHAGEN, Denmark; July 17, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that worldwide net trade sales of...